Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

• Prif Awduron: Qiao Liu (Awdur), Zhen Zhou (Awdur), Xia Luo (Awdur), Lidan Yi (Awdur), Liubao Peng (Awdur), Xiaomin Wan (Awdur), Chongqing Tan (Awdur), Xiaohui Zeng (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Frontiers Media S.A., 2022-01-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...